Treatment for Early Prostate Cancer Associated with Type of Specialist Seen
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive. The study, co-led by a urologist and a radiation oncologist at Memorial Sloan-Kettering Cancer Center, found that patients aged 65 to 69 years old who consult a urologist are more likely to undergo surgery to remove the prostate, while those who consult a radiation oncologist and a urologist, regardless of age, usually receive radiation therapy.
New Mesothelioma Overview
Mesothelioma is a rare cancer of the tissue that lines the body's internal organs. This new section contains information on our approach and expertise in the treatment of mesothelioma, as well as individual sections on the risk factors, symptoms, diagnosis and staging, and treatment of mesothelioma. Also included are a list of our mesothelioma clinical trials and support information.
Core Facilities Offer Centralized, Specialized Expertise and State-of-the-Art Equipment
To facilitate and enhance the work of Center researchers, Memorial Sloan-Kettering maintains a system of core facilities -- specialized laboratories and data centers that offer shared services to multiple users.
Researchers Make Brain Tumor Cells More Sensitive to Radiation Therapy
Gliomas are a notoriously difficult to treat form of brain cancer, often developing resistance to chemotherapy and radiation therapy. But now, Memorial Sloan-Kettering researchers have found a way in the laboratory to make these stubborn cancer cells more sensitive to the lethal effects of radiation by tinkering with the proteins governing this resistance.
Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer
Memorial Sloan-Kettering's Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.
Living Beyond Cancer Calendar
Our Living Beyond Cancer section of the Web site includes a calendar with searchable listings of upcoming survivorship workshops, support groups, and events.
About Herbs, Botanicals & Other Products
Presented by our Integrative Medicine Service, these pages provide evidence-based information about herbs, botanicals, supplements, and more.
